drugset / Trial / NCT07611110
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
RandomizedParallel-groupSingle-blindTreatment
Summary
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Timeline
- Start
- 2026-05-04
- Primary completion
- 2029-02-13
- Completion
- 2029-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD2265 | Unknown | — | — |
| Comparator | Abiraterone acetate | Small molecule | — | Oral |
| Comparator | Apalutamide | Small molecule | — | Oral |
| Comparator | Cabazitaxel | Other / unclassified | — | Intravenous |
| Comparator | Darolutamide | Other / unclassified | — | Oral |
| Comparator | Enzalutamide | Other / unclassified | — | Oral |
| Comparator | Radium-223 | Other / unclassified | — | — |
| Comparator | Rezvilutamide | Unknown | — | Oral |